SCHEMBL368935

SCHEMBL368935

CNCc1nn(-c2cnn(C)c2)ccc1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.34
RIPK2 O43353 1/20 0.33
CYP2C9 P11712 1/20 0.33
GAA P10253 1/20 0.32
ALDH1A1 P00352 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
MARK3 P27448 1/20 0.32
KMT2A Q03164 3/20 0.32
POLB P06746 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
MEN1 O00255 1/20 0.31
KDM4E B2RXH2 1/20 0.31
BRD4 O60885 1/20 0.31
PRMT5 O14744 1/20 0.30
WDR77 Q9BQA1 1/20 0.30
FYN P06241 1/20 0.30
AHR P35869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158835 0.85 CYP2C9 (0.35) KDM5ARIPK2CYP2C9GAAALDH1A1
SCHEMBL173996 0.83 CYP2C9 (0.37) KDM5ARIPK2CYP2C9GAAALDH1A1
SCHEMBL13275627 0.82 KDM5A (0.31) KDM5ACYP2C9
SCHEMBL2365038 0.80 KDM5A (0.34) KDM5ACYP2C9PRMT5WDR77
SCHEMBL13275402 0.78 CYP2C9 (0.30) CYP2C9
SCHEMBL2221734 0.78 HSD17B13 (0.37) FYN
SCHEMBL13275626 0.77 CYP2C9 (0.33) CYP2C9GAAHTTMARK3BRD4
SCHEMBL13465630 0.77 FYN (0.45) CYP2C9ALDH1A1SMN1; SMN2HTTKMT2A
SCHEMBL13275030 0.77 KMT2A (0.38) KDM5ARIPK2CYP2C9GAAALDH1A1
SCHEMBL359649 0.76 GFER (0.33) KDM5AGAASMN1; SMN2KMT2AFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET KDM5A 584/4885RIPK2 1130/4885CYP2C9 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.